ARS Pharmaceuticals Inc. (SPRY) announced the submission of a supplemental New Drug Application (sNDA) for neffy 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who weigh 15 to 30 kg. Pharmacokinetic (PK) data for neffy 1mg were slightly higher than that of adults who receive the same dose and pharmacodynamic (PD) response was similar.
The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg (66 lbs.) or more.
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children, the company said.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.